Compare LABT & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LABT | DKI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.6K | 718.2K |
| IPO Year | 2026 | 2025 |
| Metric | LABT | DKI |
|---|---|---|
| Price | $0.20 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 607.7K | ★ 14.5M |
| Earning Date | 11-18-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.04 |
| 52 Week High | $6.85 | $9.13 |
| Indicator | LABT | DKI |
|---|---|---|
| Relative Strength Index (RSI) | 16.87 | 50.52 |
| Support Level | N/A | $0.29 |
| Resistance Level | $2.13 | $2.43 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 1.52 | 63.21 |
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.